Gibson succeeds Amanda Whiting, who will return to Australia to assume a new role within the broader IAG group. Whiting has led the New Zealand division since 2021 and is credited with steering the ...

Marsha D’Souza, Associate Director of Capital Markets, explains how IAM positions fixed income as a strategic source of diversification, income and capital stability.

Earlier in the week, energy and mining names helped stabilise trade against global rate jitters and sharp bitcoin weakness, while Monday’s session was marred by an ASX outage and broad selling in ...

Rio Tinto projects potential EBITDA to be 40 to 50 per cent above 2024 levels, based on long-term prices. This ambitious target hinges on the successful execution of these cost-saving measures.

Premier Investments is facing headwinds as indicated by its recent annual general meeting update, according to RBC Capital Markets analyst Michael Toner. The update suggests ongoing softness in the ...

Dec 2025 - ASX-listed company grapples with revenue overstatements, government investigations, and shareholder uncertainty ...

Dexus has successfully priced $500 million of subordinated notes in the Australian domestic market, buoyed by robust investor demand. The issuance is split evenly between two tranches: $250 million in ...

According to Oh, the transition from traditional synchronous generation from coal and gas to inverter-based renewable energy sources diminishes the inherent stability of the electricity grid. This ...

Premier Investments Limited (PMV) has announced an on-market share buyback program for up to $100 million. The 12-month buyback follows the company’s completion of the sale of its Apparel Brands to ...

BetMakers has formalised an agreement to acquire the assets and liabilities of the Las Vegas Dissemination Company (LVDC). This acquisition provides BetMakers with direct access to major casino ...

Dec 2025 - Dr Leearne Hinch, CEO, outlines progress toward a first-in-class ovarian cancer screening test and a next generation cell-free therapy for solid tumours.

Dec 2025 - Neuromodulation company begins trading, valued at approximately $775 million after raising capital.